In Parkinson's treatment, which class of medications is a first-line option besides levodopa?

In the context of Parkinson's treatment, aside from levodopa, monoamine oxidase B (MAO-B) inhibitors are indeed recognized as a first-line medication option. MAO-B inhibitors, such as selegiline and rasagiline, work by preventing the breakdown of dopamine in the brain, which helps to enhance and prolong the effect of dopamine. This mechanism is particularly beneficial in the early stages of Parkinson’s disease, where the objective is to manage symptoms without the extensive side effects associated with higher doses of levodopa.

This class of medications can also provide a neuroprotective effect, which may slow the progression of the disease, and often they are used in combination with levodopa to improve overall treatment efficacy. Their role is especially valuable for patients who are newly diagnosed and looking to maintain their quality of life.

In contrast, anticholinergics are also used in treatment but are generally more effective for tremor control in younger patients rather than as a first-line therapy for all patients. Selective serotonin reuptake inhibitors (SSRIs) are primarily used for treating depression and anxiety and do not target the motor symptoms of Parkinson's directly. Benzodiazepines are used for anxiety and sleep disorders but are not indicated for managing